Member Info for BuenaVista

Well, today...

"Today's recommendation from our system is to SELL. The BEARISH DESCENDING HAWK pattern has finally received confirmation because the prices crossed below the confirmation level at 70.50, and our valid average selling price now stands at 69.77. The previous BUY signal was issued on 11/03/2026, 6 days ago, when the stock price was 69.00. Since then, AVCT.L has risen by +1.12%."

In other news...

"You may find yourself emotionally challenged today by a strong force demanding your attention. Your hyperawareness to every situation might be driving you a bit crazy. Perhaps you just need to tone things down and relax. Enjoy rather than question the fun-loving energy of the day. The more you simply let loose and explore, the better off you'll be."

"likely", "unlikely", "due"

"I continue to be right"

Bigly self-unaware.😂😂😂

😂 'but I continue to be right...' ...is a very telling phrase.

What you see on LSE are only an assignment of buys and sells dependent on where the mid-price is.

Yeah, I'm sure Avacta would love to conclude the SGC part of the trial and put the results out there if only it weren't for that pesky PFS which just keeps being out of reach.

How did you know?!

AACR abstracts are out tomorrow - https://x.com/TVR5AVCT/status/2033488971750162622/photo/1

If previous years are anything to go by, I'd expect more AVA6207 preclinical data, further what was presented last October at AACR-NCI-EORTC, and more AVA6103 data, maybe some of the IND submission data such as the dog study.

It would also be nice to have an update on AVA7100 and/or a total surprise topic.

Oops! Not ESMO (that's in the Autumn), ASCO (American Society of Clinical Oncology). I should have followed LDA's link.

AACR is the American Association for Cancer Research and the presentations tend to be preclinical development and specialised topics such as the AI trial design and PK and antitumour activity that Avacta presented last year along with the AVA6103 preclinical data.

CC said updated AVA6000 data will be presented at a medical conference so I guess that will be at ESMO (European Society for Medical Oncology) at the end of May.

Yes Hammy, on 6 March:

"Simon Bennett has gone from the Executive Leadership Team on the Leadership page so I presume he is no longer acting as Chief Business Officer. However his email address is still being given as the contact on the Partnering and Pipeline pages."

I also suggested they use a dedicated Business Development mailbox but you can't tell Americans anything.

Complete incompetence. Pipeline page still has Simon Bennett as contact and email address and the email address link doesn't work and probably never did - it has a full stop at the end, thus invalidating it.

The Yulii Bogatyrenko email address is outside the avacta.com email domain. Do they really want a contract worker conducting business outside their oversight? Could they not create an in-house email address for him??

Today's announcement was 'open for recruiting' so you've still got a couple of days.

Patents are not granted on the science/invention being 'proven' although being capable of industrial exploitation (utility) IS a criterion, albeit a superfluous one as if it isn't capable of being utilised, why bother patenting it?...(except to block that particular path for others).

The other two criteria are novelty and inventive step and hopefully AVA6103 and AVA6207 will pass these but it's not a done deal until they do.

Remember that AVA6000 is protected by a granted patent and that affords a certainty that is not available to AVA6103 (or AVA6207) where patents are just at the application stage.

Yes, I didn't mean a takeover bid but rather the sort of news where there are a lot of wannabe buyers and very few sellers (why would there be ANY sellers?)

Don't count on being able to buy on HL the day the big news drops. I don't know whether other platforms would be working that day when the trade volume is so high.

"Today we are 75p v £11.10..........let us see who can get to £20 first."

"£12.00 v 73p now."

Jesus F Christ, do you not understand how company valuations work? You may be doing this as a bit of competitive fun but... 🤷🏻‍♂️

...AbbVie, Bayer, Glaxo, Johnson & Johnson, Pfizer, Roche, Takeda, ...

Really, there's a lot of potential bidders.

Gmcc has given the timeframe that goes for all the PK data:

"Timepoints are collected from pre-dose on Day 1 through 48 hours post-dose (Day 3) of the first cycle as well as from pre-dose on Day 1 through 24 hours post-dose (Day 2) in each subsequent cycle."

So anything from a week (one cycle) to three/four weeks (Q2W/Q3W second cycle) to see how the data compare with the animal data.

As regards scanning the tumour, what timeframes did they use for the animal model(s) measurements? – I'm away from my PC atm.

Wise p people read the question. Intelligent prior understand the question.

Let's just say 'before they scan the tumour'.